

Progress in the treatment
of advanced breast cancer:

Spotlight on selective CDK4&6 inhibitors

Monday 10 October 2016

18:30–20:00

Rome Auditorium

Copenhagen, Denmark

Programme

18:30–18:35

Welcome and introduction

Fatima Cardoso (Lisbon, Portugal)

18:35–18:55

Lessons learned from the past: CDK4&6 inhibition over time

Angelo Di Leo (Prato, Italy)

18:55–19:15

Current insights: CDK4&6 inhibitors as a therapeutic option for HR⁺/HER2⁻ breast cancer

Fatima Cardoso (Lisbon, Portugal)

19:15–19:35

Patients' views: potential improvement through CDK4&6 inhibition

Naomi Fitzgibbon (Dublin, Ireland) and
Angelo Di Leo (Prato, Italy)

19:35–19:55

Future perspectives: implications of the use of CDK4&6 inhibitors on breast cancer management

Moderator: Lesly-Ann Martin (London, UK)

Panel: Fatima Cardoso (Lisbon, Portugal)

Angelo Di Leo (Prato, Italy)

Naomi Fitzgibbon (Dublin, Ireland)

19:55–20:00

Summary and key learning points

Fatima Cardoso (Lisbon, Portugal)

This educational activity is
provided by Elsevier with
financial support from
Lilly Oncology



ELSEVIER

Lilly | ONCOLOGY